Fusion Biopsy Market to reach US $1,001.2 million by 2028

The global fusion biopsy market is projected to reach USD 1,001.2 million by 2028, growing at a CAGR of 11.1%. Growing incidence of prostate cancer, high specificity of fusion biopsy, and increasing acceptance of multiparametric MRI in prostate cancer care are some of the factors driving the growth of the global fusion biopsy market.

Adroit Market Research report on global Fusion biopsy market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global Fusion biopsy market have been studied in detail.

Sample Report @ https://www.adroitmarketresearch.com/contacts/request-sample/1652

death in men. Most guidelines recommend screening for prostate cancer for well-informed men with more than seven to ten years of life expectancy. The process involves performing a clinical history, digital rectal examination (DRE) and serum testing of prostate specific antigen (PSA). Prostate biopsy is performed on the basis of screening results, and remains the gold standard for diagnosis.

The global fusion biopsy market is categorized based on biopsy route and end-use. On the basis of biopsy route, the market is segmented into transrectal, and transperineal. The transrectal segment dominated the market in 2020. Transrectal ultrasound guided prostate biopsy (TRUS-biopsy) is most offered worldwide. Transperineal biopsy (TPP-biopsy), on the other hand, has been gaining popularity due to its superior sensitivity and lower rate of sepsis.

North America dominated the market for fusion biopsy in 2019, while Asia Pacific is set to grow at a highest CAGR due to advances in oncology procedures. 

Key players of the global fusion biopsy market 

  • MedCom
  • Focal Helathcare
  • UC-Care Medical Systems Ltd
  • GeoScan Medical

About Us:
Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us:
Ryan Johnson
Account Manager - Global
3131 McKinney Ave Ste 600
Dallas, TX 75204

Related Posts

Subscribe Our Newsletter